US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The NCCN Guidelines now recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer

PAXMAN today announce that the National Comprehensive Cancer Network® (NCCN®) has updated the Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) to include scalp cooling as a Category 2A recommendation to reduce the incidence of chemotherapy-induced alopecia for patients receiving chemotherapy.“As PAXMAN submitted an application for consideration to the NCCN Breast Cancer Panel last year, we are pleased to announce this major positive step towards a higher quality of life for breast cancer patients undergoing chemotherapy treatment. This recommendation by NCCN is an

PAXMAN publishes newsletter on the company’s new research centre and the Board of Trade Award received from the British government

Today, PAXMAN publishes the March 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.This issue includes articles on the company’s new research centre at Huddersfield University, and the Board of Trade Award that PAXMAN recently received from the British government. Additionally, two large European orders are highlighted in an update on the ongoing order flow. To read the newsletter, and subscribe to receive upcoming issues, follow this link:http://bit.ly/paxmanmaren PAXMAN’s investor newsletter is published monthly as a part of the company’s

PAXMAN publishes its year-end report January - December 2018

After a strong fourth quarter PAXMAN exceeded its turnover target for 2018Fourth quarter 2018 · The Group’s sales volume increased to 18.4 (9.0) MSEK in the period October – December.  · Pre-tax earnings were -2.3 (-5.8) MSEK, impacted by intensified measures to increase the utilization rate of systems already installed in the US.  · EBITDA improved to -0.8 (-4.4) MSEK. · Earnings per share were -0.26 (-0.36) SEK.  · Cash flow before financing activities improved to -4.1 (-6.5) MSEK, of which a positive cash flow from operating activities of 1.6 MSEK. The strong expansion

PAXMAN and University of Huddersfield invest 12 MSEK over 5 years into world’s first scalp cooling research and development centre

PAXMAN and the University of Huddersfield have signed a five-year research and collaboration agreement covering the PAXMAN Scalp Cooling Research Centre, a new multidisciplinary research group at the University of Huddersfield. The centre will focus on biological hair follicle research as well as developing innovative scalp cooling-related treatments and individual 3D-printed cooling caps.The 12 MSEK (1 million GBP) investment in cash, staffing and other resources during the first 5 years will be jointly funded by PAXMAN and the University of Huddersfield. PAXMAN’s investment during the

PAXMAN publishes newsletter on its new CIPN indication and the double win at the EEF Future Manufacturing Awards

Today, PAXMAN publishes the February 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.In this issue, PAXMAN’s CEO comments on the company’s new project to develop a cooling device for preventing chemotherapy-induced nerve damage in hands and feet (CIPN) with National University Hospital, Singapore. Additionally, a video is included from PAXMAN’s double win at this year’s EEF Future Manufacturing Awardsin London. To read the newsletter, and subscribe to receive upcoming issues, follow this link:  http://bit.ly/

PAXMAN to develop medical cooling device to prevent nerve damage in chemotherapy patients with National University Hospital, Singapore

PAXMAN has signed a research collaboration agreement with National University Hospital, Singapore for the development of a portable cooling and compression device to prevent chemotherapy-induced peripheral neuropathy (nerve damage in hands and feet). The goal is to have a prototype ready for clinical studies in Q2 2020.This new development project creates substantial synergies for PAXMAN in both product development and global marketing/sales of cooling devices in the oncology market for side effect management. The goal is to develop a portable medical cooling product which compliments the

PAXMAN publishes newsletter on positive study results in Japan and its expanded market clearance in Malaysia

Today, PAXMAN publishes the January 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.This issue highlights positive clinical study results with PAXMAN’s scalp cooling in Japan, the world’s second largest medical technology market, as well as a recently received market clearance in Malaysia. With a population of 30 million people, Malaysia has a promising growth potential for PAXMAN in 2019 and beyond.  To read the newsletter, and subscribe to receive upcoming issues, follow this link:http://bit.ly/paxmanjanen PAXMAN’s investor newsletter is

PAXMAN receives second order from Teva in Mexico following successful market launch

PAXMAN announces that the company’s license partner Teva Pharmaceutical has ordered ten additional scalp cooling systems for Mexico after the successful market launch in November. Teva’s first order for 17 systems is currently being installed, with the first patient treatment at Centro Oncologico Internacional in Guadalajara last week.The market launch of the PAXMAN Scalp Cooling System in Mexico during a major exhibition event in Guadalajara in the middle of November was well received by leading cancer centres in the country. The demand is already substantial, and by quickly placing a

PAXMAN publishes its interim report for the period 1 July to 30 September 2018

PAXMAN’s strongest quarter to dateThe Group’s sales amounted to 39.6 (22.3) MSEK as of 30 September, of which 16.0 (8.3) MSEK in the third quarter of the year. Net loss totalled -2.8 (-6.7) MSEK as of 30 September, of which -0.3 (-1.7) MSEK refer to the period July – September. The group’s operating entities made a profit for the second quarter in a row. Earnings per share were -0.18 (-0.10) SEK for the first nine months of the year, of which -0.02 (-0.11) SEK refer to Q3.  Cash flow before financing activities was -13.8 (-15.3) MSEK for the first nine months of the year, of which -3.

PAXMAN to present the company at Stora Aktiedagen on 26 November

PAXMAN AB (publ) will give a company presentation at Stora Aktiedagen in Stockholm on 26 November. As the presentation takes place only a few days after the publication of the company’s Q3 report, PAXMAN’s CEO Richard Paxman will have the opportunity to give some more detailed comments on its contents.Stora Aktiedagen will be held at Sheraton Hotel, Tegelbacken (central Stockholm), with PAXMAN’s presentation starting at 16.00 CET in Hall 4. Attendees will be able to ask questions to CEO Richard Paxman right after the presentation.  PAXMAN’s presentation will be streamed live and on

PAXMAN publishes newsletter with information about its strong progress in the USA, Mexico and globally

PAXMAN has today published a new issue of its newsletter aimed at shareholders, investors and other interested parties. For the first time, the newsletter is published in both Swedish and English.This issue highlights the company’s strong interim report, an increased focus on enrolling more patients in the USA, the ongoing installation of the first systems in Mexico and a new long-term study confirming that scalp cooling can used to protect against permanent hair loss after chemotherapy. To read the newsletter, and subscribe to receive upcoming issues, follow this link: http://bit.ly/

PAXMAN publishes its interim report for the period 1 April to 30 June 2018

Continued expansion in line with business planThe Group’s sales amounted to 23.6 (14.0) MSEK as of 30 June, of which 12.6 (7.1) MSEK in the second quarter of the year. Net profit/loss totalled -2.5 (0.7) MSEK as of 30 June, of which -0.9 (-0.4) MSEK refer to the period April – June. Earnings per share were -0.16 (0.09) SEK for the first six months of the year, of which -0.05 (-0.03) SEK refer to Q2.  Cash flow before financing activities was -10.4 (-5.7) MSEK for the first six months of the year, of which -3.6 (-3.2) MSEK for the second quarter. Total assets amounted to 45.4 (50.0)

PAXMAN receives first order from Teva in Mexico for 17 scalp cooling systems

PAXMAN announces that the company has received a first order from its license partner Teva Pharmaceutical Industries Ltd for 17 scalp cooling systems to Mexico. The systems are to be installed at five cancer centres, three of which will install systems in Mexico City.The order marks a strong start for PAXMANs launch in Mexico since the market approval in April of 2018. At the same time, it is completely in line with the substantial interest that the company has received from both cancer centres and patients in Mexico. “There are a number of renowned cancer centres in Mexico that want to

Information on insider transactions in PAXMAN AB (publ)

PAXMAN AB (publ) announces that the company’s two largest shareholders, Glenn Paxman and Björn Littorin, have sold 250,000 shares each in the company, i.e. 500,000 shares in total. The shares were acquired by Länsförsäkringar Blekinge, Länsförsäkringar Kalmar län and a limited number of private, long-term investors. Glenn Paxman now owns 6,538,645 shares in PAXMAN, and Björn Littorin owns 1,035,076 shares.As a result of the transaction, Länsförsäkringar Blekinge and Länsförsäkringar Kalmar län now strengthen their positions as two of the company’s ten largest shareholders. The

PAXMAN comments on AMA decision on CPT code for scalp cooling

The AMA (American Medical Association) in the USA has decided not to introduce a specific CPT code that would facilitate patient cost reimbursement for scalp cooling at this time. The decision is largely based on the fact that the patient base is not yet considered to be sufficient. PAXMAN expects AMA to review its position as scalp cooling gradually becomes more common in the USA.As previously communicated by PAXMAN, the company welcomes AMA's work to introduce a CPT code for all FDA approved scalp cooling treatments. PAXMAN is not responsible for the application to the AMA, but the

PAXMAN publishes newsletter with information on its expanded FDA clearance and newly published, strong clinical results

PAXMAN has today published a new issue of its newsletter aimed at Swedish shareholders, investors and other interested parties.This issue highlights the company’s FDA clearance for solid tumours in the USA, the market approval in Mexico, progress in the approval process in Japan and recently published clinical studies where PAXMAN scalp cooling delivered very strong results. In addition to this, CEO Richard Paxman gives his impressions from the company’s attendance at ASCO, the world’s largest oncology conference.  To read the newsletter (in Swedish only), and to subscribe, follow this

PAXMAN announces FDA clearance for an expanded indication of its scalp cooling system in the US

PAXMAN’s advanced scalp cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumours. The expanded FDA clearance substantially increases the potential number of new cancer patients per year that the system can be marketed to in the USA – from an estimated 250,000 breast cancer patients to over one million breast cancer and solid tumour cancer patients.PAXMAN’s 510k application for expanded use of its scalp cooling system was submitted to the US Food and Drug Administration (FDA) in October 2017, and was thereafter

Press release from PAXMAN AB’s 2018 Annual General Meeting

PAXMAN´s first AGM was held today, 24 May 2018, at NetPort in Karlshamn. Slightly more than 83 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a company presentation and responded to questions from the attending shareholders.In accordance with the proposal submitted by the Nomination Committee, the AGM resolved that the Board of Directors shall consist of six Board Members without deputy members. The Board was re-elected in its entirety, and will thus consist of the following members up to the AGM 2019: Per-Anders Johansson (Chairman of

PAXMAN publishes its interim report for the period 1 January to 31 March 2018

A strong first quarterThe Group’s sales amounted to 11.0 MSEK in the first quarter of the year, with a net loss totalling -1.7 MSEK. Earnings per share were -0.10 SEK for the period. Cash flow before financing activities was -6.8 MSEK. Total assets amounted to 43.7 MSEK at 31 March, and net liquid assets to -1.2 MSEK. Equity to assets ratio was 71.7 % at the end of the reporting period. The 10 MSEK credit line secured earlier this year is yet to be utilized. In the first quarter of the year, PAXMAN signed a license agreement for Mexico with Teva Pharmaceutical Industries, which means

PAXMAN supplements application for expanded FDA clearance in the USA

PAXMAN AB (publ) has supplemented the company’s premarket notification application to the US FDA for an expanded indication by responding to a request for additional information. The application seeks to expand use of the company’s scalp cooling to reduce the likelihood of chemotherapy-induced alopecia (CIA) in cancer patients with solid tumors.The additional information, that has been submitted to and received by the FDA, consists of an in-depth analysis of the clinical results provided as the basis for the expanded indication. “The clinical results for our expanded FDA application

PAXMAN publishes Annual Report for 2017

PAXMAN hereby publishes its Annual Report for the financial year 2017.The Annual Report is attached to this press release, and may also be downloaded from the company’s website http://www.paxman.se/investor-centre/financial-information/?lang=en.  The attached document contains a condensed version of the complete Swedish annual report “Årsredovisning 2017”. The Swedish version is also available in the printed form and can be ordered from eva.jonasson@paxman.se. The Annual Report has been produced in cooperation with PAXMAN’s IR-partner Honeybadger, http://www.hbadger.com.

PAXMAN amends acquisition value of Paxman Group Ltd and year-end figures

PAXMAN informs that the company has changed its accounting treatment regarding the acquisition of Paxman Group Limited.Updated accounting treatment of internal acquisition improves PAXMAN’s net profit by 1.1 MSEKIn 2017 PAXMAN AB (publ) acquired the entire issued share capital of Paxman Group Limited by means of a share for share exchange. This transaction was one between legal entities under common control and as such PAXMAN AB (publ) has now been advised by its auditor that it should have been accounted for as an internal group restructuring rather than as an acquisition. The results as

PAXMAN receives market approval in Mexico and plans Q2 launch with license partner Teva Pharmaceutical Industries Ltd

PAXMAN announces that the company has received market approval in Mexico for its market leading scalp cooling system which reduces hair loss during chemotherapy treatment. PAXMAN and license partner Teva will now increase their activities in preparation for an official launch later in the second quarter.The market approval in Mexico is equivalent to the company's FDA clearance in the USA. It thus gives the right to market and sell the scalp cooling system for use in connection with chemotherapy treatment of cancer. “I am excited that we have received market approval in Mexico even

There are no items matching the current filter
There are no more items matching the current filter
Back to top